{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:44Z","timestamp":1788952364783,"version":"build-2803163510"},"reference-count":177,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,11]]},"DOI":"10.1093\/jcag\/gwy071","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T07:10:14Z","timestamp":1547190614000},"page":"6-29","source":"Crossref","is-referenced-by-count":150,"title":["Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)"],"prefix":"10.1093","volume":"2","author":[{"given":"Paul","family":"Moayyedi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N","family":"Andrews","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"MacQueen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Korownyk","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Marsiglio","sequence":"additional","affiliation":[{"name":"Unaffliated"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Graff","sequence":"additional","affiliation":[{"name":"Department of Clinical Health Psychology, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Kvern","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Lazarescu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Paterson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Sidani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Vanner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"2019042409331343000_CIT0001","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"2019042409331343000_CIT0002","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2019042409331343000_CIT0003","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/gutjnl-2015-311240","article-title":"The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review","volume":"66","author":"Sperber","year":"2017","journal-title":"Gut"},{"issue":"1","key":"2019042409331343000_CIT0004","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1013208713670","article-title":"Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire","volume":"47","author":"Thompson","year":"2002","journal-title":"Dig Dis Sci"},{"key":"2019042409331343000_CIT0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(16)32513-6","article-title":"Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [Abstract Mo1642]","volume":"150","author":"Palsson","year":"2016","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0006","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0007","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2019042409331343000_CIT0008","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"issue":"7650","key":"2019042409331343000_CIT0009","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"2019042409331343000_CIT0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA institute process for developing clinical practice guidelines part one: Grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2019042409331343000_CIT0011","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"2019042409331343000_CIT0012","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2016.12.032","article-title":"Clinical practice guidelines for the use of video capsule endoscopy","volume":"152","author":"Enns","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"2019042409331343000_CIT0013","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"2019042409331343000_CIT0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"2019042409331343000_CIT0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: CANADIAN Association of Gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0016","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jcag\/gwx008","article-title":"Clinical practice guidelines for the assessment of uninvestigated esophageal dysphagia","volume":"1","author":"Liu","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"issue":"7652","key":"2019042409331343000_CIT0017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2019042409331343000_CIT0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/archinternmed.2009.22","article-title":"Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"issue":"4","key":"2019042409331343000_CIT0019","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1023\/A:1022897028030","article-title":"Presentations of adult celiac disease in a nationwide patient support group","volume":"48","author":"Zipser","year":"2003","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2019042409331343000_CIT0020","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2019042409331343000_CIT0021","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ajg.2016.308","article-title":"Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation","volume":"111","author":"Sood","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2019042409331343000_CIT0022","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2013.08.048","article-title":"Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care","volume":"145","author":"Ford","year":"2013","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-230X-13-80","article-title":"Low prevalence of \u2018classical\u2019 microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea","volume":"13","author":"Hilmi","year":"2013","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"2019042409331343000_CIT0024","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s00535-012-0573-4","article-title":"Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: A prospective multi-center study utilizing colonoscopy","volume":"47","author":"Ishihara","year":"2012","journal-title":"J Gastroenterol"},{"issue":"4","key":"2019042409331343000_CIT0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ajg.2010.55","article-title":"The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: Results from a prospective, controlled US trial","volume":"105","author":"Chey","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2019042409331343000_CIT0026","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00384-011-1163-2","article-title":"Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case\u2013control study","volume":"26","author":"Gu","year":"2011","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"2019042409331343000_CIT0027","first-page":"CR363","article-title":"Organic colonic lesions in patients with irritable bowel syndrome (IBS)","volume":"12","author":"Akhtar","year":"2006","journal-title":"Med Sci Monit"},{"issue":"5","key":"2019042409331343000_CIT0028","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1572-0241.1999.01077.x","article-title":"Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria","volume":"94","author":"Hamm","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2019042409331343000_CIT0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4081\/gi.2011.e3","article-title":"The prevalence of inflammatory bowel diseases, microscopic colitis, and colorectal cancer in patients with irritable bowel syndrome","volume":"3","author":"El-Salhy","year":"2011","journal-title":"Gastroenterol Insights"},{"issue":"2","key":"2019042409331343000_CIT0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3906\/sag-1401-88","article-title":"Two gastrointestinal conditions with similar symptoms and endoscopic appearance: Irritable bowel syndrome and microscopic colitis","volume":"45","author":"\u015eim\u015fek","year":"2015","journal-title":"Turk J Med Sci"},{"key":"2019042409331343000_CIT0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-230X-11-96","article-title":"The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome","volume":"11","author":"Ozdil","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2019042409331343000_CIT0032","first-page":"39","article-title":"[Prevalence of microscopic colitis in patients with irritable bowel syndrome with diarrhea predominance]","volume":"76","author":"Carmona-S\u00e1nchez","year":"2011","journal-title":"Rev Gastroenterol Mex"},{"issue":"2","key":"2019042409331343000_CIT0033","first-page":"133","article-title":"Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome","volume":"66","author":"Tun\u00e7er","year":"2003","journal-title":"Acta Gastroenterol Belg"},{"issue":"6","key":"2019042409331343000_CIT0034","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/00365521.2012.666672","article-title":"Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting","volume":"47","author":"De Silva","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"2019042409331343000_CIT0035","doi-asserted-by":"crossref","first-page":"e0166922","DOI":"10.1371\/journal.pone.0166922","article-title":"Trends in irritable bowel syndrome incidence among Taiwanese adults during 2003\u20132013: A population-based study of sex and age differences","volume":"11","author":"Pan","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"2019042409331343000_CIT0036","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gut.2008.159723","article-title":"Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis","volume":"57","author":"Ford","year":"2008","journal-title":"Gut"},{"issue":"4","key":"2019042409331343000_CIT0037","first-page":"203","article-title":"Measures of diagnostic accuracy: Basic definitions","volume":"19","author":"\u0160imundi\u0107","year":"2009","journal-title":"ejifcc"},{"issue":"25","key":"2019042409331343000_CIT0038","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJM199412223312501","article-title":"a prospective study of family history and the risk of colorectal cancer","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"23","key":"2019042409331343000_CIT0039","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1001\/jama.2016.5989","article-title":"Screening for colorectal cancer: US preventive services task force recommendation statement","volume":"315","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"key":"2019042409331343000_CIT0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1503\/cmaj.151125","article-title":"Recommendations on screening for colorectal cancer in primary care","volume":"188","author":"Bacchus","year":"2016","journal-title":"CMAJ"},{"issue":"11","key":"2019042409331343000_CIT0041","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/j.1572-0241.2002.07027.x","article-title":"The utility of diagnostic tests in irritable bowel syndrome patients: A systematic review","volume":"97","author":"Cash","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2019042409331343000_CIT0042","doi-asserted-by":"crossref","first-page":"e106478","DOI":"10.1371\/journal.pone.0106478","article-title":"The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: A cohort study","volume":"9","author":"Canavan","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"2019042409331343000_CIT0043","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1046\/j.1365-2036.2003.01646.x","article-title":"The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study","volume":"17","author":"Thomson","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2019042409331343000_CIT0044","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3109\/00365521.2015.1007079","article-title":"Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: Cross-sectional survey","volume":"50","author":"Patel","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"2019042409331343000_CIT0045","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.gie.2005.08.016","article-title":"Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome","volume":"62","author":"Spiegel","year":"2005","journal-title":"Gastrointest Endosc"},{"issue":"23","key":"2019042409331343000_CIT0046","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.2016.3332","article-title":"Screening for colorectal cancer: Updated evidence report and systematic review for the us preventive services task Force","volume":"315","author":"Lin","year":"2016","journal-title":"JAMA"},{"key":"2019042409331343000_CIT0047","doi-asserted-by":"crossref","first-page":"g2467","DOI":"10.1136\/bmj.g2467","article-title":"Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: Systematic review and meta-analysis of randomised controlled trials and observational studies","volume":"348","author":"Brenner","year":"2014","journal-title":"BMJ"},{"key":"2019042409331343000_CIT0048","first-page":"71","article-title":"The epidemiology of irritable bowel syndrome","volume":"6","author":"Canavan","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"10","key":"2019042409331343000_CIT0049","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"issue":"8","key":"2019042409331343000_CIT0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2982.2005.00745.x","article-title":"Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review","volume":"18","author":"Park","year":"2006","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"2019042409331343000_CIT0051","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.gtc.2010.12.012","article-title":"Food: The forgotten factor in the irritable bowel syndrome","volume":"40","author":"Eswaran","year":"2011","journal-title":"Gastroenterol Clin North Am"},{"issue":"11","key":"2019042409331343000_CIT0052","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1398-9995.1996.tb04471.x","article-title":"Prevalence of adverse reactions to food in patients with gastrointestinal disease","volume":"51","author":"Bischoff","year":"1996","journal-title":"Allergy"},{"issue":"7","key":"2019042409331343000_CIT0053","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1572-0241.1999.01226.x","article-title":"Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients","volume":"94","author":"Dainese","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2019042409331343000_CIT0054","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ajg.2013.105","article-title":"Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life","volume":"108","author":"B\u00f6hn","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2019042409331343000_CIT0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nurpra.2015.12.007","article-title":"Addressing the role of food in irritable bowel syndrome symptom management","volume":"12","author":"Capili","year":"2016","journal-title":"J Nurse Pract"},{"issue":"2","key":"2019042409331343000_CIT0056","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000051878","article-title":"Food-related gastrointestinal symptoms in the irritable bowel syndrome","volume":"63","author":"Simr\u00e9n","year":"2001","journal-title":"Digestion"},{"issue":"1","key":"2019042409331343000_CIT0057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004836-199607000-00005","article-title":"Does lactose maldigestion really play a role in the irritable bowel","volume":"23","author":"Tolliver","year":"1996","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"2019042409331343000_CIT0058","first-page":"117","article-title":"Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactose-free diet","volume":"27","author":"Vernia","year":"1995","journal-title":"Ital J Gastroenterol"},{"issue":"3","key":"2019042409331343000_CIT0059","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00042737-200103000-00001","article-title":"Irritable bowel syndrome: Is the search for lactose intolerance justified","volume":"13","author":"Parker","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"2019042409331343000_CIT0060","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/BF01299809","article-title":"Lactose malabsorption and intolerance in Italians. Clinical implications","volume":"31","author":"Bozzani","year":"1986","journal-title":"Dig Dis Sci"},{"issue":"10","key":"2019042409331343000_CIT0061","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00042737-199610000-00015","article-title":"The clinical relevance of lactose malabsorption in irritable bowel syndrome","volume":"8","author":"B\u00f6hmer","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"2019042409331343000_CIT0062","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00042737-200108000-00011","article-title":"The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: A 5-year follow-up study","volume":"13","author":"B\u00f6hmer","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"2019042409331343000_CIT0063","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5056\/jnm.2010.16.1.40","article-title":"Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea","volume":"16","author":"Ghoshal","year":"2010","journal-title":"J Neurogastroenterol Motil"},{"key":"2019042409331343000_CIT0064","doi-asserted-by":"crossref","first-page":"S929","DOI":"10.1016\/S0016-5085(16)33149-3","article-title":"Glucose breath test in patients with overlapping FD and IBS. Is there any difference compared to patients with only FD or only IBS? [Abstract Tu1738]","volume":"150","author":"Sosa","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"2019042409331343000_CIT0065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5009\/gnl16126","article-title":"Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy","volume":"11","author":"Ghoshal","year":"2017","journal-title":"Gut Liver"},{"issue":"12","key":"2019042409331343000_CIT0066","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2019042409331343000_CIT0067","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41395-018-0195-4","article-title":"A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome","volume":"113","author":"Dionne","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2019042409331343000_CIT0068","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2019042409331343000_CIT0069","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial","volume":"149","author":"B\u00f6hn","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"2019042409331343000_CIT0070","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial","volume":"66","author":"McIntosh","year":"2017","journal-title":"Gut"},{"issue":"8","key":"2019042409331343000_CIT0071","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3945\/jn.112.159285","article-title":"Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome","volume":"142","author":"Staudacher","year":"2012","journal-title":"J Nutr"},{"key":"2019042409331343000_CIT0072","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(16)30842-3","article-title":"The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration: a 2X2 factorial randomized controlled trial [Abstract 1133]","volume":"150","author":"Staudacher","year":"2016","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0073","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jgh.13688","article-title":"Nutritional, microbiological and psychosocial implications of the low FODMAP diet","volume":"32","author":"Staudacher","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2019042409331343000_CIT0074","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2013.386","article-title":"Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI","volume":"109","author":"Murray","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2019042409331343000_CIT0075","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1365-2036.2010.04237.x","article-title":"Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon","volume":"31","author":"Barrett","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2019042409331343000_CIT0076","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2016.09.062","article-title":"Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome","volume":"152","author":"Major","year":"2017","journal-title":"Gastroenterology"},{"key":"2019042409331343000_CIT0077","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jhn.12114","article-title":"A dietary survey of patients with irritable bowel syndrome","volume":"27","author":"Hayes","year":"2014","journal-title":"J Hum Nutr Diet"},{"issue":"1","key":"2019042409331343000_CIT0078","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","article-title":"Diets that differ in their FODMAP content alter the colonic luminal microenvironment","volume":"64","author":"Halmos","year":"2015","journal-title":"Gut"},{"key":"2019042409331343000_CIT0079","first-page":"131","article-title":"Efficacy of the low FODMAP diet for treating irritable bowel syndrome: The evidence to date","volume":"9","author":"Nanayakkara","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"2019042409331343000_CIT0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ajg.2010.487","article-title":"Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial","volume":"106","author":"Biesiekierski","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2019042409331343000_CIT0081","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.3390\/nu7064542","article-title":"Non-celiac gluten sensitivity has narrowed the spectrum of irritable bowel syndrome: A double-blind randomized placebo-controlled trial","volume":"7","author":"Shahbazkhani","year":"2015","journal-title":"Nutrients"},{"key":"2019042409331343000_CIT0082","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2013.04.051","article-title":"No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates","volume":"145","author":"Biesiekierski","year":"2013","journal-title":"Gastroenterology"},{"issue":"9","key":"2019042409331343000_CIT0083","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jand.2012.06.009","article-title":"Gluten-free diet: Imprudent dietary advice for the general population","volume":"112","author":"Gaesser","year":"2012","journal-title":"J Acad Nutr Diet"},{"issue":"4","key":"2019042409331343000_CIT0084","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2036.2010.04386.x","article-title":"Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet","volume":"32","author":"Wild","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2019042409331343000_CIT0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-277X.2007.00763.x","article-title":"Economic burden of a gluten-free diet","volume":"20","author":"Lee","year":"2007","journal-title":"J Hum Nutr Diet"},{"issue":"9","key":"2019042409331343000_CIT0086","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2014.195","article-title":"The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis","volume":"109","author":"Moayyedi","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019042409331343000_CIT0087","doi-asserted-by":"crossref","first-page":"828137","DOI":"10.1155\/2014\/828137","article-title":"Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: A pilot, randomized controlled study","volume":"2014","author":"Kamiya","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1-2","key":"2019042409331343000_CIT0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.01.028","article-title":"Psyllium as therapeutic and drug delivery agent","volume":"334","author":"Singh","year":"2007","journal-title":"Int J Pharm"},{"issue":"3","key":"2019042409331343000_CIT0089","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1142\/S0192415X15500251","article-title":"A systematic review of integrated traditional Chinese and Western medicine for managing irritable bowel syndrome","volume":"43","author":"Li","year":"2015","journal-title":"Am J Chin Med"},{"issue":"7","key":"2019042409331343000_CIT0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3748\/wjg.v18.i7.589","article-title":"Herbal medicines for the management of irritable bowel syndrome: A comprehensive review","volume":"18","author":"Rahimi","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2019042409331343000_CIT0091","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3748\/wjg.14.454","article-title":"Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: A systematic review","volume":"14","author":"Shi","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2019042409331343000_CIT0092","first-page":"CD005111","article-title":"Acupuncture for treatment of irritable bowel syndrome","author":"Lim","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2019042409331343000_CIT0093","first-page":"CD005111","article-title":"Acupuncture for treatment of irritable bowel syndrome","author":"Manheimer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2019042409331343000_CIT0094","doi-asserted-by":"crossref","first-page":"e13040","DOI":"10.1111\/nmo.13040","article-title":"Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial","volume":"29","author":"Lowe","year":"2017","journal-title":"Neurogastroenterol Motil"},{"issue":"7311","key":"2019042409331343000_CIT0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.323.7311.485","article-title":"Adverse events following acupuncture: Prospective survey of 32 000 consultations with doctors and physiotherapists","volume":"323","author":"White","year":"2001","journal-title":"BMJ"},{"key":"2019042409331343000_CIT0096","doi-asserted-by":"crossref","first-page":"432467","DOI":"10.1155\/2015\/432467","article-title":"Systematic review of adverse effects: A further step towards modernization of acupuncture in China","volume":"2015","author":"Wu","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"issue":"7","key":"2019042409331343000_CIT0097","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/ijd.12914","article-title":"Adverse events associated with acupuncture: A clinicopathologic review","volume":"55","author":"Park","year":"2016","journal-title":"Int J Dermatol"},{"key":"2019042409331343000_CIT0098","doi-asserted-by":"crossref","first-page":"a2313","DOI":"10.1136\/bmj.a2313","article-title":"Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis","volume":"337","author":"Ford","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"2019042409331343000_CIT0099","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s10620-009-0854-9","article-title":"The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome","volume":"55","author":"Merat","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2019042409331343000_CIT0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2019042409331343000_CIT0101","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jep.2016.10.083","article-title":"Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome","volume":"194","author":"Mosaffa-Jahromi","year":"2016","journal-title":"J Ethnopharmacol"},{"issue":"6","key":"2019042409331343000_CIT0102","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCG.0b013e3182a88357","article-title":"Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis","volume":"48","author":"Khanna","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"2019042409331343000_CIT0103","first-page":"397","article-title":"Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome","volume":"20","author":"Kabir","year":"2011","journal-title":"Mymensingh Med J"},{"key":"2019042409331343000_CIT0104","doi-asserted-by":"crossref","first-page":"824605","DOI":"10.1155\/2013\/824605","article-title":"Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial","volume":"2013","author":"Ko","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"2019042409331343000_CIT0105","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.nut.2014.02.010","article-title":"Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome","volume":"30","author":"Stevenson","year":"2014","journal-title":"Nutrition"},{"issue":"1","key":"2019042409331343000_CIT0106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.12787","article-title":"Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2013a 12 week double-blind study","volume":"40","author":"Sisson","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2019042409331343000_CIT0107","first-page":"466","article-title":"Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating","volume":"17","author":"Jafari","year":"2014","journal-title":"Arch Iran Med"},{"issue":"5","key":"2019042409331343000_CIT0108","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/nmo.12320","article-title":"Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients","volume":"26","author":"Ludidi","year":"2014","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"2019042409331343000_CIT0109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jgh.12322","article-title":"Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial","volume":"29","author":"Yoon","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2019042409331343000_CIT0110","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MEG.0000000000000094","article-title":"Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial","volume":"26","author":"Abbas","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"26","key":"2019042409331343000_CIT0111","doi-asserted-by":"crossref","first-page":"8709","DOI":"10.3748\/wjg.v20.i26.8709","article-title":"I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life","volume":"20","author":"Lorenzo-Z\u00fa\u00f1iga","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2019042409331343000_CIT0112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.dld.2014.11.007","article-title":"A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome","volume":"47","author":"Pineton de Chambrun","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2019042409331343000_CIT0113","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10620-014-3299-8","article-title":"Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study","volume":"60","author":"Wong","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2019042409331343000_CIT0114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3164\/jcbn.15-14","article-title":"Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial","volume":"57","author":"Yoon","year":"2015","journal-title":"J Clin Biochem Nutr"},{"issue":"1","key":"2019042409331343000_CIT0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MEG.0000000000000484","article-title":"Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome","volume":"28","author":"Thijssen","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2019042409331343000_CIT0116","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2050640615602571","article-title":"Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation","volume":"4","author":"Spiller","year":"2016","journal-title":"United European Gastroenterol J"},{"issue":"48","key":"2019042409331343000_CIT0117","doi-asserted-by":"crossref","first-page":"10631","DOI":"10.3748\/wjg.v22.i48.10631","article-title":"Irritable bowel syndrome symptom severity improves equally with probiotic and placebo","volume":"22","author":"Lyra","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2019042409331343000_CIT0118","doi-asserted-by":"crossref","first-page":"e13037","DOI":"10.1111\/nmo.13037","article-title":"A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS","volume":"29","author":"Hod","year":"2017","journal-title":"Neurogastroenterol Motil"},{"issue":"10","key":"2019042409331343000_CIT0119","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2019042409331343000_CIT0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MCG.0b013e318225f545","article-title":"How patients view probiotics: Findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome","volume":"46","author":"Mercer","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"2019042409331343000_CIT0121","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019042409331343000_CIT0122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1099-1700(199801)14:1<31::AID-SMI754>3.0.CO;2-B","article-title":"Stress and contingency management in the treatment of irritable bowel syndrome","volume":"14","author":"Fernandez","year":"1998","journal-title":"Stress Med"},{"issue":"3","key":"2019042409331343000_CIT0123","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12529-012-9241-6","article-title":"Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: A randomized wait-list controlled trial","volume":"20","author":"Zernicke","year":"2013","journal-title":"Int J Behav Med"},{"issue":"6","key":"2019042409331343000_CIT0124","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/1359105315573450","article-title":"Gut-directed guided affective imagery as an adjunct to dietary modification in irritable bowel syndrome","volume":"20","author":"Boltin","year":"2015","journal-title":"J Health Psychol"},{"key":"2019042409331343000_CIT0125","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2019042409331343000_CIT0126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0005-7967(92)90141-3","article-title":"Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome","volume":"30","author":"Blanchard","year":"1992","journal-title":"Behav Res Ther"},{"issue":"5","key":"2019042409331343000_CIT0127","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1037\/0022-006X.63.5.779","article-title":"A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome","volume":"63","author":"Payne","year":"1995","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"2019042409331343000_CIT0128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0016-5085(91)90215-7","article-title":"A controlled trial of psychological treatment for the irritable bowel syndrome","volume":"100","author":"Guthrie","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"2019042409331343000_CIT0129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.psy.0000116964.76529.6e","article-title":"Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome","volume":"66","author":"Simr\u00e9n","year":"2004","journal-title":"Psychosom Med"},{"key":"2019042409331343000_CIT0130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cpr.2016.11.001","article-title":"Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis","volume":"51","author":"Laird","year":"2017","journal-title":"Clin Psychol Rev"},{"issue":"4","key":"2019042409331343000_CIT0131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2036.2011.04730.x","article-title":"Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome","volume":"34","author":"Clav\u00e9","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2019042409331343000_CIT0132","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/1319-3767.145331","article-title":"Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study","volume":"20","author":"Rai","year":"2014","journal-title":"Saudi J Gastroenterol"},{"issue":"7","key":"2019042409331343000_CIT0133","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.cgh.2015.01.015","article-title":"Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, Controlled Trial","volume":"13","author":"Zheng","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2019042409331343000_CIT0134","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: A clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"2019042409331343000_CIT0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S2215-0366(17)30126-8","article-title":"Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): A double-blind, randomised study","volume":"4","author":"Agger","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"18","key":"2019042409331343000_CIT0136","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2165\/0003495-200868180-00007","article-title":"Antidepressants for the treatment of chronic pain","volume":"68","author":"Verdu","year":"2008","journal-title":"Drugs"},{"issue":"2","key":"2019042409331343000_CIT0137","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00535-012-0726-5","article-title":"Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases","volume":"48","author":"Grover","year":"2013","journal-title":"J Gastroenterol"},{"issue":"2","key":"2019042409331343000_CIT0138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.1994.tb00273.x","article-title":"Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome","volume":"8","author":"Gorard","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2019042409331343000_CIT0139","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2036.2008.03633.x","article-title":"Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome","volume":"27","author":"Vahedi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2019042409331343000_CIT0140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2036.2005.02566.x","article-title":"The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study","volume":"22","author":"Vahedi","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2019042409331343000_CIT0141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphar.2013.00045","article-title":"Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved","volume":"4","author":"Renoir","year":"2013","journal-title":"Front Pharmacol"},{"issue":"3","key":"2019042409331343000_CIT0142","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner","year":"2006","journal-title":"Am Fam Physician"},{"issue":"3","key":"2019042409331343000_CIT0143","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/13543784.2013.761205","article-title":"The use of psychotropic drugs in irritable bowel syndrome","volume":"22","author":"Dekel","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2019042409331343000_CIT0144","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2019042409331343000_CIT0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome\u2013a double-blind placebo controlled study","volume":"130","author":"Lav\u00f6","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"3","key":"2019042409331343000_CIT0146","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2019042409331343000_CIT0147","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"2019042409331343000_CIT0148","first-page":"S11","article-title":"Loperamide: A pharmacological review","volume":"7","author":"Baker","year":"2007","journal-title":"Rev Gastroenterol Disord"},{"issue":"1","key":"2019042409331343000_CIT0149","first-page":"15","article-title":"The role of loperamide in gastrointestinal disorders","volume":"8","author":"Hanauer","year":"2008","journal-title":"Rev Gastroenterol Disord"},{"issue":"7","key":"2019042409331343000_CIT0150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"30","author":"Wedlake","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2019042409331343000_CIT0151","first-page":"A54","article-title":"A reason why lactose-free diet can be clinically ineffective in lactose intolerance patients [Abstract OP165]","volume":"3","author":"Lombardo","year":"2015","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"2019042409331343000_CIT0152","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"2019042409331343000_CIT0153","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"2019042409331343000_CIT0154","doi-asserted-by":"crossref","first-page":"A545","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: SHORT term treatment leading to long term sustained response [Abstract T1390]","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"2019042409331343000_CIT0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"2019042409331343000_CIT0156","volume-title":"XIFAXAN\u00ae (Rifaximin) Prescribing Information, May 2015"},{"issue":"4","key":"2019042409331343000_CIT0157","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2019042409331343000_CIT0158","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1046\/j.1365-2036.2000.00808.x","article-title":"Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms","volume":"14","author":"Di Stefano","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2019042409331343000_CIT0159","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"2019042409331343000_CIT0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for Irritable Bowel Syndrome with Diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"2019042409331343000_CIT0161","first-page":"15","article-title":"Eluxadoline in the treatment of irritable bowel syndrome with diarrhea","volume":"8","author":"Smith","year":"2016","journal-title":"Clin Med Rev Ther"},{"key":"2019042409331343000_CIT0162","volume-title":"VIBERZITM (Eluxadoline) Product Monograph, Jan 2017"},{"issue":"7","key":"2019042409331343000_CIT0163","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2004.02.020","article-title":"Irritable bowel syndrome and surgery: A multivariable analysis","volume":"126","author":"Longstreth","year":"2004","journal-title":"Gastroenterology"},{"issue":"8","key":"2019042409331343000_CIT0164","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1365-2036.2003.01499.x","article-title":"Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome","volume":"17","author":"Hasler","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"2019042409331343000_CIT0165","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1463-1318.2009.01990.x","article-title":"A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome","volume":"12","author":"Awad","year":"2010","journal-title":"Colorectal Dis"},{"issue":"9","key":"2019042409331343000_CIT0166","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: Macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2019042409331343000_CIT0167","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2019042409331343000_CIT0168","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: Phase two study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2019042409331343000_CIT0169","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome\u2013results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2019042409331343000_CIT0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.mcg.0000225665.68920.df","article-title":"Lubiprostone: A chloride channel activator","volume":"41","author":"Lacy","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"26","key":"2019042409331343000_CIT0171","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable Bowel Syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"key":"2019042409331343000_CIT0172","doi-asserted-by":"crossref","first-page":"S741","DOI":"10.1016\/S0016-5085(16)32517-3","article-title":"Efficacy and safety of linaclotide in patients with IBS-C: Results from a phase 3, randomized, double-blind, placebo-controlled trial in China and other regions [Abstract Mo1646]","volume":"150","author":"Yang","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"2019042409331343000_CIT0173","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"2019042409331343000_CIT0174","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2019042409331343000_CIT0175","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2019042409331343000_CIT0176","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40265-013-0157-5","article-title":"Linaclotide: A review of its use in the treatment of irritable bowel syndrome with constipation","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"2019042409331343000_CIT0177","volume-title":"CONSTELLATM (Linaclotide) Product Monograph, May 2014"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcag\/article-pdf\/2\/1\/6\/28514194\/gwy071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T19:56:09Z","timestamp":1720900569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/2\/1\/6\/5290372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,17]]},"published-print":{"date-parts":[[2019,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwy071","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,1,17]]}}}